SABCS | Conferences

Oral Paclitaxel Improves Response, Reduces Peripheral Neuropathy in Metastatic Breast Cancer

December 18th 2019, 6:57pm


Patients with metastatic breast cancer who received an oral version of the chemotherapy drug experienced improved response rates and reductions in peripheral neuropathy compared to those who took the drug intravenously.

Men with Breast Cancer Must Attend Major Conferences to Advocate for Themselves

December 18th 2019, 3:00am


At the 2019 San Antonio Breast Cancer Symposium, Khevin Barnes advocated on behalf of men with breast cancer, but also advocated for more men with breast cancer to join him.

Circulating Tumor DNA After Neoadjuvant Chemo May Determine Risk of Recurrence in TNBC

December 18th 2019, 1:00am


Patients with early-stage triple-negative breast cancer who did not have circulating tumor DNA in their blood experienced superior outcomes to chemotherapy followed by surgery.

Measuring Residual Cancer Burden Could Help Improve Predictions of Breast Cancer Outcomes

December 16th 2019, 7:17pm


Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.

Menopausal Hormone Therapy with Estrogen Alone Decreases Breast Cancer Incidence

December 14th 2019, 12:00am


Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.

Partial Breast Irradiation Is Effective in Preventing Recurrence in Patients with Early-Stage Breast Cancer

December 13th 2019, 10:00pm


Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.

Awareness for Men With Breast Cancer is Starting to Take Hold at Major Conferences

December 13th 2019, 9:00pm


This massive event for women with breast cancer just may be “man’s breast friend”.

Arimidex Extends Benefit of Breast Cancer Recurrence Prevention in Postmenopausal Women

December 13th 2019, 3:00am


Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.

Adding Immunotherapy to Chemo Before Surgery May Not Improve Response Rates in TNBC

December 13th 2019, 12:41am


Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.

Keytruda Plus Chemotherapy Before and After Surgery Improves Response in Certain Patients with Triple-Negative Breast Cancer

December 12th 2019, 10:31pm


Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.